OMER News and Press, Omeros Corporation From 11/12/19

Omeros Corporation (OMER) Q3 2019 Earnings Conference Call November 12, 2019 04:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman & Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Conference Call Participants ...

Omeros (NASDAQ: OMER ): Q3 GAAP EPS of -$0.33 beats by $0.05 . Revenue of $29.9M (+548.6% Y/Y) beats by $2.71M . Press Release More news on: Omeros Corporation, Earnings news and commentary, Healthcare stocks news,

Conference Call Today at 4:30 p.m. ET Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation,...

Omeros (NASDAQ: OMER ) is scheduled to announce Q3 earnings results on Tuesday, November 12th, after market close. The consensus EPS Estimate is -$0.41 (+42.3% Y/Y) and the consensus Revenue Estimate is $27.19M (+489.8% Y/Y). Over the last 2 years, omer has beaten EPS estimates 50% o...

ADPT , ADT , BREW , CBPX , CDLX , CPRX , DDOG , DOX , HALO , HCAT , HIIQ , HTHT , HUYA , KWR , MCRN , MTSI , OMER , PTE , RUN , SDC , SENS , SSTI , SWKS , TLRY , TVTY , TWOU , VRAY , VREX , YY For Seeking Alpha's full earnings season calendar, click here . ...

Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation entitled “Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances T-cell responses” at the American Association for Cancer Resear...

--Prestigious Prize Conferred for GPCR Program Discoveries-- Omeros Corporation (Nasdaq: OMER) today announced that three of its scientists––Alexander Gragerov, Ph.D., associate vice president of research, George A. Gaitanaris, M.D., Ph.D., chief scientific officer, and G...

Wall Street kept celebrating on Monday, delivering fresh record highs for the major benchmarks in the process. As long as trade discussions between China and the U.S. appear to be going relatively smoothly and have a chance at eventual success, investors seem willing to look past those issues an...

Omeros ( OMER -11.2% ) is down out of the gate this morning despite positive results from a prospective study that showed significantly less fentanyl use in cataract surgery patients receiving eye drop Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3%. The data were just...

Insperity (NYSE: NSP ) -27%  on Q3 results . More news on: Insperity, Inc., Omeros Corporation, Ceragon Networks Ltd., Stocks on the move, Read more ...